摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-4-苯基-2-丁烯酸 | 2243-52-9

中文名称
(E)-4-苯基-2-丁烯酸
中文别名
——
英文名称
3-benzylacrylic acid
英文别名
4-phenylbut-2-enoic acid;4-Phenyl-crotonsaeure;4-Phenylbutenoesaeure;γ-Phenylcrotonsaeure;4-phenyl-crotonic acid
(E)-4-苯基-2-丁烯酸化学式
CAS
2243-52-9
化学式
C10H10O2
mdl
——
分子量
162.188
InChiKey
SCBUQIQXUBOQAI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    64-65 °C
  • 沸点:
    137-138 °C(Press: 2 Torr)
  • 密度:
    1.130±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    12
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

SDS

SDS:a15797fbd12dd82b307ac498d2747bae
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Synthesis of cyanofuroxans from 4-nitrofuroxans via C C bond forming reactions
    作者:Ryosuke Matsubara、Akihiro Ando、Masahiko Hayashi
    DOI:10.1016/j.tetlet.2017.07.015
    日期:2017.8
    direct synthesis process. The optimized reaction conditions showed an excellent applicability for the synthesis of a range of 4-cyanofuroxans. 3-Cyanofuroxans, known to be thiol-mediated nitric oxide donors, could also be obtained by the thermal or photochemical isomerization of 4-cyanofuroxans. The developed cyanation of furoxans is a rare example of CC bond-forming reaction on a furoxan ring.
    描述了4-硝基呋喃烷的取代反应以制备4-氰基呋喃烷。逆反应使该取代反应复杂化,明智地选择氰化物源对于实现这种直接合成过程很重要。优化的反应条件显示出极好的适用于合成一系列4-氰基呋喃聚糖。3-氰基呋喃类,已知是硫醇介导的一氧化氮供体,也可以通过4-氰基呋喃类的热或光化学异构化获得。呋喃喃的发达氰化反应是呋喃环上形成C C键的罕见反应。
  • The studies on the chemoenzymatic synthesis of 2-benzyl-3-butenoic acid
    作者:Filip Borys、Daniel Paprocki、Dominik Koszelewski、Ryszard Ostaszewski
    DOI:10.1016/j.catcom.2018.05.020
    日期:2018.8
    The studies on the chemoenzymatic synthesis of 2-benzyl-3-butenoic acid 3 were performed. The alkylation of dienolates derived from the crotonic and vinylacetic acids with different types of alkylating agents was examined. In all cases the inseparable mixture of isomeric acids 3 and 4 were obtained. Chemoselective enzymatic esterification of those mixtures provides ester 6 in 86% yield as a single
    化学合成2-苄基-3-丁烯酸3的研究。检查了来自巴豆酸和乙烯基乙酸的二烯酸酯与不同类型的烷基化剂的烷基化。在所有情况下,均获得了异构体3和4的不可分离的混合物。这些混合物的化学选择性酶促酯化以单一产物形式提供酯6,收率为86%,而没有双键异构化。没有一种通用的方法可用于其水解,因为在碱性条件下仅形成异构酸5。为了克服该限制,设计了酶催化的水解过程。该方案以98%的产率提供了异​​构纯的酸3。
  • Selective oxidation of aromatic primary alcohols to aldehydes using molybdenum acetylide oxo-peroxo complex as catalyst
    作者:Ankush V. Biradar、Mohan K. Dongare、Shubhangi B. Umbarkar
    DOI:10.1016/j.tetlet.2009.03.178
    日期:2009.6
    Selective oxidation of various aromatic alcohols to aldehydes has been carried out with very high conversion (90%) and selectivity (90%) for aldehydes using cyclopentadienyl molybdenum acetylide complex, CpMo(CO)3(CCPh) (1) as catalyst and hydrogen peroxide as environmentally benign oxidant. Water-soluble Mo acetylide oxo-peroxo species is formed in situ after reaction of 1 with aqueous hydrogen peroxide
    使用环戊二烯基乙炔钼络合物,CpMo(CO)3(C CPh)(1)作为催化剂和氢气,已以很高的转化率(90%)和对醛的选择性(90%)进行了各种芳香醇选择性氧化为醛的反应。过氧化物作为对环境无害的氧化剂。1的反应后在原位形成水溶性的乙炔酸钼氧-过氧物质在反应过程中用过氧化氢水溶液作为催化活性物质。有趣的是,即使催化剂是均相的,通过使用分液漏斗分离有机相中的产物和水相中的催化剂,也可以非常容易地将其再循环。即使经过五次循环,也没有观察到明显的醇转化率和醛选择性损失。
  • Knoevenagel-Doebner condensation promoted by chitosan as a reusable solid base catalyst
    作者:Nagaraj Anbu、Surendran Hariharan、Amarajothi Dhakshinamoorthy
    DOI:10.1016/j.mcat.2019.110744
    日期:2020.3
    although Knoevenagel-Doebner condensation reaction has been reported with many organocatalysts including proline, no attempts were made to develop heterogeneous catalysts with environmental concerns. Considering these factors in mind, the title reaction is studied with chitosan as a heterogeneous solid base catalyst for the synthesis of α,β-unsaturated carboxylic acids through the condensation followed
    使用天然存在的生物聚合物开发绿色和可持续性工艺正成为替代传统催化系统的合适方法之一,传统催化系统会产生大量具有高风险因素的副产物。在这种情况下,尽管已经报道了Knoevenagel-Doebner与包括脯氨酸在内的许多有机催化剂的缩合反应,但未尝试开发涉及环境问题的多相催化剂。考虑到这些因素,以壳聚糖为多相固体碱催化剂研究了标题反应,该反应通过缩合然后脱羧反应合成α,β-不饱和羧酸。壳聚糖具有许多优势,例如浸出,可重复使用性测试,广泛的底物范围,并以更高的纯度提供所需产品的更高产量。粉末X射线衍射(XRD),傅立叶变换红外光谱(FT-IR),扫描电子显微镜(SEM)和元素分析表明,在优化反应条件下,催化前后壳聚糖的结构完整性和形态没有重大变化。情况。
  • Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl)
    申请人:Rhone-Poulenc Rorer Pharmaceuticals Inc.
    公开号:US06057369A1
    公开(公告)日:2000-05-02
    This invention is directed to compounds of formula I: ##STR1## wherein the variables are as described herein. Compounds within the scope of the present invention possess useful properties, more particularly pharmaceutical properties. They are especially useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. Compounds within the scope of the present invention may also inhibit an MMP, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting MMPs, such disease states involve tissue breakdown and those associated with a physiologically detrimental excess of TNF. The present invention is therefore also directed to the pharmaceutical use of the compounds, pharmaceutical compositions containing the compounds, intermediates leading thereto and methods for the preparation of the compounds and their intermediates.
    本发明涉及式I的化合物:##STR1## 其中变量如本文所述。本发明所涵盖的化合物具有有用的性质,特别是药物性质。它们在治疗患有与生理有害的肿瘤坏死因子(TNF)过度相关的疾病状态的患者中抑制TNF的产生或生理效应特别有用。本发明所涵盖的化合物还抑制环磷酸腺苷磷酸二酯酶,并且在治疗与抑制环磷酸腺苷磷酸二酯酶有关的病理条件的疾病状态中有用,这些疾病状态包括炎症和自身免疫性疾病,特别是第四型环磷酸腺苷磷酸二酯酶。本发明所涵盖的化合物还可能抑制MMP,并且在治疗与抑制MMP有关的病理条件的疾病状态中有用,这些疾病状态涉及组织分解和与TNF过度有害相关的疾病状态。因此,本发明还涉及化合物的药物用途、含有该化合物的药物组合物、导致其中间体的中间体以及制备该化合物及其中间体的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐